Version Changes
Revised. Amendments from Version 1
The reporting on place of residence for a study has been amended with reference to Table 6S. The fourth paragraph of the Discussion has had a sentence added that acknowledges the restrictions of data capture for different jurisdictions. The final paragraph of the Discussion has been updated to explain the focus on high impact journals, to acknowledge that different journals have different policies about what can be reported and uploaded with an article, and acknowledged the limitations of the search strategy.
Abstract
Background
This review examines whether randomised controlled trials (RCTs) of surgery in orthopaedics are inclusive of their target populations, including under-served populations.
Methods
The BMJ, Journal of the American Medical Association, The Lancet, and The New England Journal of Medicine were electronically searched in February 2022 for eligible RCTs published from 1 January 2014. Screening, key baseline patient characteristics, the inclusion of under-served groups and whether patient recruitment was pragmatic in design were key data extracted. The findings were tabulated and reported narratively.
Results
There were 26 RCTs included that were parallel in design and conducted across a range of countries in different hospital settings. Four RCTs did not report the complete CONSORT statement. There was variation in the percentage of the screened population who were randomised into the studies ranging from 5.8% to 74.7%. Most RCTs were pragmatic in design regarding patient selection but this did not necessarily translate to an inclusive trial population. Only two RCTs reported the age and gender of all screened patients. All 26 RCTs reported the age and gender of randomised patients but only four studies reported ethnicity. Reporting about the consideration and inclusion of under-served populations was limited.
Conclusions
There is variation in the exclusion of patients of the target population. Reporting of key patient characteristics during screening and attention given to under-served populations in the design, conduct and reporting of these trials is limited. Training and education on inclusivity is required along with practical guidance about how to implement this. To improve inclusivity in the screening and recruitment of patients there should be a focus on (i) screening and eligibility criteria, (ii) collection and reporting on attributes to ensure no section of the eligible population is inadvertently excluded, and (iii) embedding mechanisms to allow all eligible patients the opportunity to participate.
Keywords: Inclusivity; Under-served; Orthopaedics; Surgery; Randomised trials; Review
Plain Language Summary
Orthopaedic surgical trials often aim to evaluate surgery in real-world settings, including a wide range of participants to reflect the target population. This approach helps ensure the research is relevant to clinical practice and that the findings can be widely applied. The National Institute for Health and Care Research (NIHR) in the United Kingdom is focusing on improving the inclusion of under-represented groups in healthcare research, such as those of different ages, educational backgrounds, and language abilities. Including diverse participants in trials is crucial to avoid missing important findings and to prevent discrimination. This review looked at whether orthopaedic surgical trials are inclusive of their target populations, including under-served groups. It included 26 trials from various countries and hospital settings. The review found that there is variation in how patients are excluded, limited reporting of key patient characteristics, and insufficient attention to under-served populations in the design and conduct of these trials. Training and education on inclusivity is required along with practical guidance about how to implement this. To make trials more inclusive and representative, there should be a focus on the following (i) the criteria for screening and eligibility, (ii) collecting and reporting information to ensure no eligible group is left out, and (iii) create ways for all eligible patients to participate.
Introduction
Orthopaedic surgical randomised controlled trials (RCTs) are often pragmatically designed to evaluate whether surgery is an effective intervention in a realistic clinical setting 1, 2 . The evaluation of surgery, lends itself to a pragmatic approach, by its complex nature 1 . A critical aim of a pragmatic approach is to be inclusive of a broad sample of participants that will reflect the target population in clinical practice and maximise the generalisability of findings.
Differences in recruitment across sites, however, is common in pragmatic RCTs 3 . This can result in recruited patients differing from those who are not recruited across characteristics such as age, sex, ethnicity, severity of disease, educational status, social class, and place of residence 4 . Reviews show that trials consistently fail to report participant flow accurately, particularly before informed consent and randomisation 5, 6 . As it is not always clear how many patients were screened for inclusion and why they were not randomised, the results may not be accepted by the surgical community. The National Institute for Health and Care Research (NIHR), the United Kingdom’s (UK) largest public funder of trials, has begun to focus on the inclusion of under-represented groups in health care research. Various grouping have been suggested for consideration and include the following: demographic factors (e.g. age, sex, ethnicity); social and economic factors (e.g. employment, socio-economic status, geographic location, language, digitally excluded); and health status (e.g. mental health condition, cognitive impairment, physical disabilities) 7, 8 . Inclusivity in trials is important for improving representation of the target population so important findings specific to different populations are not missed and to avoid potential discrimination towards historically under-served populations. More money, time and effort may be required to be more inclusive, but may lend itself to research that is representative of the whole patient population and as a result, is more informative for patient and clinical decision-making 8 .
For orthopaedic surgical trials, the focus has been on improving internal validity 1, 9 rather than on their applicability to practice 10 . A criticism of such trials has been that the screening, choice, and application of eligibility criteria has meant many patients are excluded. This may affect whether clinicians accept the results of a trial if not considered to be reflective of their usual patients. Treatments may then not be used that could benefit patients and optimise the efficient use of NHS resources, or alternatively, are continued to be used when they have limited clinical and/or cost-effectiveness. This lack of representation has been interpreted as limiting the applicability of the findings of orthopaedic surgical trials 11, 12 and can delay their translation into practice and increase research waste 13 .
In the absence of literature exploring the applicability of orthopaedic surgical trials, that such trials have been criticised for a lack of patient representation, and the emerging policy to be inclusive of underserved groups we judged it was timely to conduct a review on this topic. We chose to focus on orthopaedic trials that are published in high impact medical journals that are likely to have high visibility and potential to influence key stakeholders and clinical practice 12 . The aim of this review of high impact journals was to examine whether published findings of RCTs of surgery in orthopaedics are inclusive of their target populations and suggest practical recommendations for encouraging inclusivity by design in future orthopaedic surgical trials.
Methods
Patient and Public Involvement
There was no Patient and Public involvement in this research.
We adapted systematic review methodology to robustly review current methodological practice in orthopaedic surgical trials. To optimise study design and transparency in our reporting the protocol and the findings are aligned with the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) checklist and the PRISMA guidance 14, 15 . The review was prospectively registered with Research on Research hub ( https://ror-hub.org/study/1955/).
Eligibility criteria
Individually randomised trials that included an orthopaedic patient population defined as involving bone or joint disorders were eligible for inclusion. Trials must have included surgery compared with: other surgical intervention(s); non-operative (i.e. did not involve surgery) interventions; or a placebo-control. Surgery was defined as any interventional procedure that changes the anatomy and requires a skin incision or the use of endoscopic techniques; dental studies were excluded. Placebo refers to a surgical placebo, a sham surgery, or an imitation procedure intended to mimic the active intervention. This includes when a scope is inserted and nothing was done but patients were sedated or under general anaesthesia and could not distinguish whether or not they underwent the actual procedure 16 . RCTs could be conducted anywhere but only articles written in the English language were included.
Information sources and search strategy
The BMJ, Journal of the American Medical Association (JAMA), The Lancet, and The New England Journal of Medicine (NEJM) were chosen as examples of top-ranking medical journals and electronically searched in February 2022 for eligible RCTs published from 1 January 2014. That year was chosen as it is when concerns were raised about the DRAFFT trial and the number of patients excluded 11, 17 . For the BMJ, the date to filter from 01/01/2014 to 06/02/2022 (defaults to today’s date) was selected, “Research” as the type of article and by “trial” in the title. For the Lancet, the publication range could be customised from January 2014 to February 2022. The search terms “randomised” and “trial” were selected to be in the title of “The Lancet” journal and then results selected on Research Article. For JAMA, the search term used was “randomized clinical trial”, then for article type “research” was selected and for content type “article” with a customised date range of 1 January 2014 to 6 February 2022. Finally, for the NEJM, the term “randomized” was used to search within the abstract, “research” for article category and a date range of 2014/01/01 to 2022/02/28).
Study selection
One reviewer screened all titles and abstracts to identify potentially eligible studies. Full manuscripts of potentially relevant studies were assessed by the reviewer against the eligibility criteria and independently checked by a second reviewer (LA, CK, EC, KH, JN, JA). Disagreements over eligibility were resolved through discussion or recourse to a third reviewer (SB).
Data extraction
A data extraction form was developed in Microsoft Excel and piloted using six studies to assess eligibility and two studies for data extraction. Data collected from the piloting of the form was not included in the review. Data were extracted from the main publication and supplementary files by one reviewer and checked by a second reviewer (LA, CK, EC, KH, JN, JA). Disagreements over data extraction were resolved through discussion or recourse to a third reviewer (SB).
Data items
Information extracted included author, year, study design (e.g. parallel, factorial), country, setting (e.g. number of trauma hospitals/major trauma centres), target patient population (e.g. top level of the CONSORT 18 statement flowchart or equivalent in text), eligibility criteria, recruitment period, intervention/comparator(s), number of patients (screened, excluded, not consented, randomised), reasons for exclusion, recruitment (i.e. where e.g. clinic, ward, intensive care units; how e.g. search medical databases, media advertising, use of incentives) and age (years), gender and ethnicity of patients.
Data extracted about under-served populations and patients being able to consent included: language barriers (e.g. translation, literacy); allowance for disability (e.g. visual/hearing impairment); electronic data collection (i.e. digital disadvantage); and lack of capacity to consent for themselves 19 .
Domains of the PRECIS-2 tool were used to rate whether recruitment of patients was pragmatic on a scale of 1 to 5 (i.e. very explanatory, rather explanatory, equally pragmatic and explanatory, rather pragmatic, very pragmatic) for eligibility, recruitment and setting 20 . This was undertaken by one reviewer (NJ) and checked by a second reviewer (JD) and, if necessary, recourse to a third reviewer (SB).
Quality appraisal was not undertaken as it was not an effectiveness review.
Data synthesis
A narrative and tabular summary of key study characteristics is provided, including the target patient population and eligibility criteria.
The following numbers of patients are presented: (i) screened for enrolment; (ii) excluded based on eligibility criteria; (iii) did not consent; and (iv) randomised. These numbers are presented for all included trials and stratified by the type of comparator.
Age, gender and ethnicity of patients at baseline are summarised descriptively for (i) screened (entire sample); (ii) ineligible (excluded patients); (iii) non-consenting; and (iv) randomised patients. This is presented for all trials and stratified by the type of comparator.
A fixed effects meta-analysis to explore heterogeneity in baseline characteristics (i.e. age, gender, ethnicity) between patients screened but not randomised and those randomised using the I 2 statistic was planned 21 . This was not feasible as there were too few studies, nor for this reason was the planned subgroup analyses about how pragmatic was the trial design or type of comparator.
Finally, whether under-served patient populations were considered including facilitators to consent and whether the trials were pragmatic in the selection and recruitment of patients is tabulated.
Results
Study selection
3,030 potentially eligible studies were identified. After screening the title and abstract, there was full retrieval of journal articles for 27 studies; one was subsequently excluded that did not include surgery 22 . Therefore 26 studies were included 17, 23– 47 . Figure 1 summarises the study selection process. Table 1S in the extended data gives a detailed description of the eligibility criteria and patient population.
Figure 1. Flowchart of included studies.
Study characteristics
Table 2S summarises the study characteristics. All studies were parallel in design, four included a sham or placebo-control 25, 41, 42, 47 , and were conducted across a wide range of countries in different hospital settings. Nine studies did not clearly report where recruitment was undertaken 17, 23, 24, 32, 34, 36, 37, 39, 47 ; among those that did, recruitment took place in locations including out-patient clinics, fracture clinics, wards, and emergency departments. Twelve studies did not report how recruitment was conducted 17, 23, 24, 28, 31, 33, 34, 39– 42, 47 . For the remaining studies, recruitment included screening by trial co-ordinators/research associates, review by individual or expert panel of surgeons, or new admissions by surgical teams. The detailed eligibility criteria of the included trials are available in Figshare repository for which further details are in the Data Availability section.
Completion of the CONSORT statement
Table 1 describes the number of patients screened for enrolment, excluded, eligible, non-consenting and randomised as reported in the CONSORT flowchart. Four studies did not fully complete the reporting of patients in the study 17, 28, 29, 36 . There was variation in the percentage of the screened and eligible population who were randomised ranging from 5.8% up to 74.7% and 30.1% up to 92.4%, respectively. This occurred within studies of different comparators with the surgical intervention.
Table 1. CONSORT statement flowchart.
| Author (year) | Surgery
comparator |
Number of
patients screened |
Number of
patients excluded |
Number of
patients eligible |
Number of
patients not consenting |
Number of patients
randomised (% of screened & % of eligible) |
|---|---|---|---|---|---|---|
| Rangan et al., 2020 | Multiple
comparators |
914 | 116 | 798 | 295 | 503 (55.0% & 63.0%) |
| Skou et al., 2015 | Non-operative
intervention |
1475 | 1348 | 127 | 27 | 100 (6.8% & 78.7%) |
| Bailey et al., 2020 | Non-operative
intervention |
790 | 622 | 168 | 40 | 128 (16.2% & 76.2%) |
| Willett et al., 2016 | Non-operative
intervention |
2015 | 1344 | 671 | 51 | 620 (30.8% & 92.4%) |
| Rangan et al., 2015 | Non-operative
intervention |
1250 | 687 | 563 | 313 | 250 (20.0% & 44.4%) |
| van de Graaf et al., 2018 | Non-operative
intervention |
Not reported | Not reported | Not reported | Not reported | 321 |
| Rämö et al., 2020 | Non-operative
intervention |
321 | 181 | 140 | 58 | 82 (25.5% & 58.6%) |
| Costa et al., 2022 | Non-operative
intervention |
2636 | 1936 | 700 | 196 | 504 (19.1% & 72.0%) |
| Griffin et al., 2014 | Non-operative
intervention |
2006 | 1504 | 502 | 351 | 151 (7.5% & 30.1%) |
| Kise et al., 2016 | Non-operative
intervention |
341 | 115 | 226 | 85 | 140 a (41.0% & 61.9%) |
| Palmer et al., 2019 | Non-operative
intervention |
495 | 145 | 350 | 128 | 222 (44.8% & 63.4%) |
| Reijman et al., 2021 | Non-operative
intervention |
Not reported | Not reported | 282 | 115 | 167 (N/A & 59.2%) |
| Dias et al., 2020 | Non-operative
intervention |
1047 | 272 | 775 | 336 | 439 (41.9% & 56.6%) |
| Griffin et al., 2018 | Non-operative
intervention |
6028 | 5380 | 648 | 268 b | 348 c (5.8% & 53.7%) |
| Ghogawala et al., 2016 | Other surgery | Not reported | Not reported | 130 | 64 d | 66 (N/A & 50.8%) |
| Försth et al., 2016 | Other surgery | 358 | 59 | 299 | 52 | 247 (69.0% & 82.6%) |
| Ghogawala et al., 2021 | Other surgery | 458 | 168 | 290 | 127 e | 163 (35.6% & 56.2%) |
| Costa et al., 2017 | Other surgery | 537 | 131 | 406 | 85 | 321 (59.8% & 79.1%) |
| Costa et al., 2014 | Other surgery | Not reported | Not reported | 639 | 178 | 461 (N/A & 72.1%) |
| Faith investigators, 2018 | Other surgery | 7306 | 5609 | 1697 f | 589 | 1108 (15.2% & 65.3%) |
| HIP ATTACK
investigators, 2020 |
Other surgery | 27701 | 19921 | 7780 | 532 g | 2970 (10.7% & 38.2%) |
| Beard et al., 2019 | Other surgery | 962 | 121 | 841 | 310 | 531 h (55.2% & 63.1%) |
| Beard et al., 2018 | Placebo
control/sham |
2975 | 2235 | 740 | 427 i | 313 (10.6% & 42.3%) |
| Paavola et al., 2018 | Placebo
control/sham |
281 | 68 | 213 | 3 | 210 (74.7% & 98.6%) |
| Firanescu et al., 2018 | Placebo
control/sham |
1280 | 944 | 336 | 156 | 180 (14.1% & 53.6%) |
| Clark et al., 2016 | Placebo control/sham | 302 | 148 | 154 | 34 | 120 (39.7% & 77.9%) |
a A further patient was not randomised as they incurred another injury following screening
b A further 29 eligible patients were not invited to randomisation consultation
c Three patients were randomised in error and did not receive treatment and were not followed-up
d This is 24 eligible who declined all participation and 40 who declined randomisation but included in an observation cohort
e Of the 127, 91 enrolled into a non-randomised cohort and 15 withdrew prior to randomisation and 21 did not wish to enrol at all/did not wish to have surgery or had surgery at another facility
f The study reports that 1843 were eligible patients; however, of these 146 were potentially eligible but missed so were not confirmed as eligible patients
g A further 4278 were eligible but not randomised for the following reasons: operating room board could not accommodate (n=1643), not identified before surgery (n=1009), surgeon not available (n=396), family did not consent (n=374), physician declined (n=231), other (n=625)
h Of 531, three were randomised twice so excluded
i Of these 427, 232 took part in an observational cohort for patients with a strong preference and 195 did not partake in the trial or cohort
Description of key baseline characteristics
Tables 3S, 4S and 5S (refer to extended data) describe the key baseline characteristics of age, gender and ethnicity for (i) screened; (ii) ineligible; (iii) non-consenting; and (iv) randomised patients. Only two studies described the characteristics of both screened (age and gender only) and randomised patients 43, 46 , so heterogeneity was not statistically explored. The same two studies did this for ineligible patients and four studies for non-consenting patients 17, 36, 43, 46 . All 26 studies reported the age and gender of randomised patients and only four studies for ethnicity 32, 34, 43, 46 .
Inclusion of under-served populations
Table 6S (refer to extended data) describes the trial populations for characteristics relevant to under-served populations. There is considerable variation in the choice of lower age limit and ten of the 26 studies (39%) specified an upper age limit (for seven this was ≤75 years) 24, 25, 28, 29, 32, 33, 36, 39, 42, 44 . Four studies described the ethnicity of trial participants 32, 34, 43, 46 . Six studies described the education of the trial participants 28, 29, 33, 40, 43, 46 . Four of those studies, did not describe the entire sample, for example, only whether college education or equivalent was met 28, 29, 33, 40 . Eight studies reported the employment status of participants 26, 28, 32, 37, 40, 43, 44, 46 . No studies reported using deprivation scores to help recruit the target population, such as selecting a sample of recruiting sites to reflect a range of geographical populations that are historically under-served by research activity. One study reported on place of residence (e.g. independent or nursing home) 23 .
Methods to facilitate consent
Methods to facilitate consent are detailed in Table 7S (refer to extended data). One study reported that language barriers were addressed with the availability of translators 46 . Two studies reported that study materials were available to potential participants in formats other than written, including the use of a DVD or verbal explanation 38, 40 . Most studies required written consent and completion of paper questionnaires. No studies reported the use of electronic or verbal consent and only three studies referred to electronic collection of questionnaires 28, 29, 45 . Few studies mentioned whether patients without capacity to consent were included in their target population (n=7) or patients being excluded for this reason (n=15). Of the remaining four studies, consent was taken by, for example, a legal guardian or was a decision made by the clinical team in the context of the Mental Health Capacity Act 2005 23, 30, 34, 36 .
Pragmatic selection of trial participants
Table 2 summarises how pragmatic studies were in their selection of patients and includes questions about eligibility, recruitment and setting. For eligibility, 19 of the 26 studies (73%) were agreed to be ‘very pragmatic’ or ‘rather pragmatic’ in design, deeming trial participants similar to those patients in usual care. For recruitment, and the extra effort to do this beyond how patients would be identified in usual care, 24 (92%) studies were ‘very pragmatic’ or ‘rather pragmatic’ in design. Then for the setting in which patients were recruited, 16 (62%) studies were ‘very pragmatic’ or ‘rather pragmatic’ in design.
Table 2. Pragmatic selection of patients into the included studies.
| Author (year) |
Eligibility—To what extent are
the participants in the trial similar to those who would receive this intervention if it was part of usual care? |
Recruitment—How much
extra effort is made to recruit participants over and above what would be used in the usual care setting to engage with patients? |
Setting—How
different are the settings of the trial from the usual care setting? |
|---|---|---|---|
| Ghogawala et al., 2016 | Very explanatory | Rather explanatory | Rather explanatory |
| Försth et al., 2016 | Rather pragmatic | Rather pragmatic | Rather pragmatic |
| Skou et al., 2015 | Equally pragmatic and explanatory | Rather pragmatic | Rather explanatory |
| Bailey et al., 2020 | Rather pragmatic | Rather pragmatic | Very explanatory |
| Willett et al., 2016 | Rather pragmatic | Rather pragmatic | Very pragmatic |
| Ghogawala et al., 2020 | Rather pragmatic | Rather pragmatic | Very pragmatic |
| Rangan et al., 2015 | Very pragmatic | Very pragmatic | Very pragmatic |
| van de Graaf et al., 2018 | Rather pragmatic | Rather pragmatic | Rather pragmatic |
| Rämö et al., 2020 | Very explanatory | Rather pragmatic | Rather explanatory |
| Costa et al., 2017 | Very pragmatic | Very pragmatic | Very pragmatic |
| Costa et al., 2014 | Rather pragmatic | Very pragmatic | Very pragmatic |
| Costa et al., 2022 | Rather pragmatic | Very pragmatic | Very pragmatic |
| Firanescu et al., 2018 | Rather explanatory | Equally pragmatic and explanatory | Equally pragmatic and
explanatory |
| Griffin et al., 2014 | Very pragmatic | Very pragmatic | Equally pragmatic and
explanatory |
| Kise et al., 2016 | Rather explanatory | Rather pragmatic | Rather explanatory |
| Paavola et al., 2018 | Rather explanatory | Rather pragmatic | Rather explanatory |
| Palmer et al., 2019 | Equally pragmatic and explanatory | Rather pragmatic | Equally pragmatic and
explanatory |
| Reijman et al., 2021 | Rather pragmatic | Rather pragmatic | Rather pragmatic |
| Beard et al., 2018 | Rather pragmatic | Very pragmatic | Very pragmatic |
| Faith investigators, 2018 | Very pragmatic | Very pragmatic | Very pragmatic |
| HIP ATTACK investigators, 2020 | Very pragmatic | Rather pragmatic | Very pragmatic |
| Dias et al., 2020 | Very pragmatic | Very pragmatic | Very pragmatic |
| Beard et al., 2019 | Very pragmatic | Very pragmatic | Very pragmatic |
| Griffin et al., 2018 | Rather pragmatic | Rather pragmatic | Rather pragmatic |
| Rangan et al., 2020 | Very pragmatic | Very pragmatic | Very pragmatic |
| Clark et al., 2016 | Rather pragmatic | Rather pragmatic | Very explanatory |
Discussion
This review of orthopaedic surgical trials published in high impact journals illustrates considerable variation in how patients are recruited that could affect clinical applicability and acceptability of trial findings. There is marked variation in patients initially screened, who meet all the eligibility criteria, provide consent and are randomised into the study. Limited data were collected about key baseline characteristics of patients who pass through the different phases of patient selection. Notably only four studies (15%) reported on ethnicity which is similar to a recent review that found only 9.3% (38 of 407) of NIHR trials demonstrated exactly how they both recorded, and reported, ethnicity 48 . Critical to understanding the selection of patients into RCTs is describing their enrolment in the flowchart of the CONSORT statement 18 . Most studies reported the different steps of enrolment but there is considerable selectivity of patients from the screened target population to who were randomised into the study. Within included studies we found limited data about ethnicity, education or employment status of patients. The methods did not explain how language barriers were addressed, and what alternative methods of data collection and enrolment of patients without capacity to consent were used. Studies were mostly pragmatic in recruitment of patients, which by definition should have clinical applicability. However, whilst judged to be pragmatic in design 20 , these findings suggest the need to think beyond what is traditionally considered to be pragmatic and truly be inclusive of all eligible patients and that of under-served populations.
Recently, a lack of patient representation in health care research has become the focus of the NIHR, the largest public funder of trials in the UK. Consequently, there has been an emphasis on including under-served groups. It is known, for example, that for musculoskeletal conditions some minority and ethnic groups are disproportionately represented because of risk factors such as levels of physical activity, vitamin D deficiency, poverty, and pre-existing long term conditions such as diabetes 49 . A recent national survey from a representative sample of 5,030 people from across the UK found nine in ten people (88%) think a diverse mix of participants in health care and research is important even if the research costs more money (70%) or takes more time (74%) 50 . Both leading funding bodies and the public expect to have inclusivity in research.
Sometimes trial teams may deliberately widen their screening to ensure every possible patient is considered for the study. Although there may be legitimate reasons for this, several included studies specified an upper age limit of ≤75 years which could proactively exclude eligible patients. When designing studies around the inclusive selection of patients and optimising the flow of patients careful consideration should be given to: defining the target population, the choice of eligibility criteria, who is involved in the screening of patients and the training they have and methods used to screen 51 , methods to minimise patient and/or surgeon preferences 52 and optimise patient recruitment 53 and involvement of patient and public collaborators 54 .
Reporting key characteristics of patients who are screened, excluded because of eligibility criteria and who are not approached or do not consent may help reassure clinicians and policy makers about the representativeness of the trial sample. The General Data Protection Regulation in the UK provides the lawful basis for processing such data and the common law of confidentiality allows the collection of data without a legal basis as long as the patient cannot be identified 55 . As an example, age could be collected in years (or age bands) or only the first part of a postcode to inform measures of deprivation. This allows the lawful and feasible collection of key characteristics of the screened population without the need for consent. A consistent approach from Research Ethics Committees/Health Research Authority and subsequent Information Governance professionals undertaking local site review is required as to what is acceptable to collect that ensures anonymity but permits reporting about inclusivity. This type of data capture may not be permissible, however, due to restrictions of different jurisdictions.
In the UK and the NIHR focus on improving inclusivity in research, frameworks are being or have been developed as to how this may be achieved 7, 8, 56 . This is part of the NIHR workstream called “Innovations in Clinical Trial Design and Delivery for the Under-served” (INCLUDE) project. This includes a roadmap that defines under-served groups and barriers to their inclusion 8 . The Ethnicity Framework launched on 1 October 2020 ( https://www.trialforge.org/trial-forge-centre/include/) aims to help trial teams think about the inclusion of ethnic groups in their trial 7 . Multiple approaches to address the barriers to inclusive participation in research include: translation of recruitment and patient questionnaires subject to appropriate validation; and provision of materials in braille, audio-recorded, or animation and apps to help those with low literacy, learning or sensory difficulty. For these tools to be universally adopted into standard trial practice, a coordinated and consistent approach is required to their implementation with a greater understanding of their resource implications to be considerate of the workforce and pressures facing the NHS.
A strength of this review was applying the PRISMA guidelines 14, 15 . The protocol was registered prospectively. It was conducted by a multi-disciplinary team of methodologists, orthopaedic surgeons and trial coordinators. The review is limited to RCTs of orthopaedic surgical trials in high impact journals that are amongst the most cited medical journals and known to the authors as having published large-scale orthopaedic surgical trials. We chose to focus on these RCTs as they are likely to be the best resourced to deliver research and influence key stakeholders and clinical practice. The review team focussed on reporting what was presented in the main publication and supplementary material available on the journal website. It is possible that details not published by the journal are available in a full monograph, in trial registries or in the published protocol; although being described in a registry or protocol does not necessarily mean it was implemented. Moreover, different journals may have different word count policies and what is permitted to be uploaded alongside an article. This review focused on the journal publication and supplementary material as that is most likely to be read by surgeons and to influence decisions in clinical practice. Several reviewers checked study inclusion and undertook data extraction that could contribute to variability in decision-making. This was to make the review feasible with the lack of resources to support it. Maintaining the standard of a second reviewer checking a first reviewer with recourse to always the same third reviewer should mitigate this limitation. Finally, identifying studies with simple search terms were undertaken of the journal website rather than an electronic database such as PUBMED as this was more feasible with the latter lacking specificity in the searches 57 . Whilst this search strategy may not meet the standards of a systematic review of effectiveness we have nevertheless undertaken a comprehensive review with the resources available to us and makes an original and timely contribution to the literature.
Conclusion
Patient selection and recruitment is a key challenge for RCTs. Different clinical pathways and differences between participating sites and resources available add to the complexity of achieving this. However, the enrolment of a highly selective sample of patients may impact on the clinical applicability and acceptability of study findings. Trials often purport to be pragmatic in design. The limited data available about who and how patients are included in these studies, questions whether they truly are pragmatic and inclusive of the target population. This review is not a criticism of existing high impact orthopaedic surgical trials that are an important contribution to the evidence-base as only recently has there been this attention towards inclusivity and improving external validity. The challenge now is to address this and ensure every person eligible to take part has the same opportunity and are not excluded whether consciously or not. This is a requirement of leading funding bodies and an expectation of the public. This may be difficult and complex to implement as it requires time, resources and funding for which there can be an opportunity cost and needs to be integrated into efficient trial design and delivery 58 . Change will also not happen on its own and needs initiatives that provide training and education on inclusivity in clinical trials 59 and practical guidance about how to implement strategies to achieve this 60 . The NIHR is starting initiatives to provide training in inclusive research design 61 and regulatory bodies are developing guidance on increasing diversity of people taking part in clinical trials 62 . The promotion of decentralised clinical trials away from trial sites could also improve inclusivity in recruitment allowing participants to overcome geographical, financial, family and work constraints 63 .
Finally, the following practical guidance could improve inclusivity in the screening and recruitment of patients into orthopaedic surgical trials:
(i) screening and eligibility criteria – including collection of data to allow complete reporting of the CONSORT flowchart 18 , careful consideration in the definition of eligibility criteria 64 , and efficient data capture methods to record data on those patients screened, eligible, approached and randomised 51 .
(ii) collection and reporting on attributes to ensure no section of the eligible population is inadvertently excluded – including, for example, collecting data during screening on age, sex, ethnicity and (first part of) postcode to inform measures of deprivation which are often not reported yet known to influence patient outcomes 4, 65, 66 .
(iii) embedding mechanisms to allow all eligible patients the opportunity to participate – including making information accessible in a variety of formats such as the translation of recruitment materials; provision of materials in braille, audio-recorded, or animation (that allows captions in different languages); and direction to apps to help read printed materials.
Ethics and consent
This study did not require any form of ethical approval or consent
Acknowledgements
There are no acknowledgements as this review was solely undertaken by the authors.
Funding Statement
This project is funded by the National Institute for Health Research (NIHR) under its [‘Health Technology Assessment Programme’ (Grant Reference Number NIHR133418)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
[version 2; peer review: 1 approved, 1 approved with reservations, 1 not approved]
Data availability
Underlying data
All data underlying the results are available as part of the article and no additional source data are required.
Extended data
Figshare: Supporting materials for review of high impact journals about inclusivity in orthopaedic surgical randomised trials
An additional file including Tables 1S to 7S of extended data is available at Figshare repository along with the trial protocol and PRISMA checklist ( https://doi.org/10.6084/m9.figshare.27074599) 67 .
This project contains the following underlying data:
Tables 1S to 7S extended data
Applicability of orthopaedic surgical trials review protocol_2023.02.02.docx
Reporting guidelines
Figshare: PRISMA checklist for “Inclusivity of the target population in orthopaedic surgical randomised trials: a review of high impact journals”. Doi: https://doi.org/10.6084/m9.figshare.27074599 67
This data is available under the terms of the Creative Commons Zero “No rights reserved” data waiver.
Author contributions
CRediT author statement: All authors contributed to conceptualization, visualization, methodology, writing – original draft, writing – review and editing. SB, LA, CK, EC, KH, JN, NAJ and JJD also contributed to data curation, investigation and validation.
References
- 1. Cook JA: The challenges faced in the design, conduct and analysis of surgical Randomised Controlled Trials. Trials. 2009;10: 9. 10.1186/1745-6215-10-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Hanzlik S, Mahabir RC, Baynosa RC, et al. : Levels of evidence in research published in The Journal of Bone and Joint Surgery (American volume) over the last thirty years. J Bone Joint Surg Am. 2009;91(2):425–8. 10.2106/JBJS.H.00108 [DOI] [PubMed] [Google Scholar]
- 3. Knowlson C, Dean A, Doherty L, et al. : Recruitment patterns in multicentre randomised trials fit more closely to price's law than the Pareto principle: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. Contemp Clin Trials. 2022;113: 106665. 10.1016/j.cct.2021.106665 [DOI] [PubMed] [Google Scholar]
- 4. Rothwell PM: External validity of Randomised Controlled Trials: “to whom do the results of this trial apply?”. Lancet. 2005;365(9453):82–93. 10.1016/S0140-6736(04)17670-8 [DOI] [PubMed] [Google Scholar]
- 5. Hopewell S, Hirst A, Collins GS, et al. : Reporting of participant flow diagrams in published reports of randomized trials. Trials. 2011;12: 253. 10.1186/1745-6215-12-253 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Toerien M, Brookes ST, Metcalfe C, et al. : A review of reporting of participant recruitment and retention in RCTs in six major journals. Trials. 2009;10: 52. 10.1186/1745-6215-10-52 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Treweek S, Banister K, Bower P, et al. : Developing the INCLUDE ethnicity framework—a tool to help trialists design trials that better reflect the communities they serve. Trials. 2021;22(1): 337. 10.1186/s13063-021-05276-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Witham MD, Anderson E, Carroll C, et al. : Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process. Trials. 2020;21(1): 694. 10.1186/s13063-020-04613-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Blencowe NS, Cook JA, Pinkney T, et al. : Delivering successful randomized controlled trials in surgery: methods to optimize collaboration and study design. Clin Trials. 2017;14(2):211–8. 10.1177/1740774516687272 [DOI] [PubMed] [Google Scholar]
- 10. Sterne JAC, Savović J, Page MJ, et al. : RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: I4869. 10.1136/bmj.l4898 [DOI] [PubMed] [Google Scholar]
- 11. Fullilove S, Gozzard C: Dorsally displaced fractures of the distal radius: a critical appraisal of the DRAFFT (Distal Radius Acute Fracture Fixation Trial) study. Bone Joint J. 2016;98-B(3):298–300. 10.1302/0301-620X.98B3.36771 [DOI] [PubMed] [Google Scholar]
- 12. Nwachukwu BU, Kahlenberg CA, Lehamn JD, et al. : Characteristics of orthopedic publications in high-impact general medical journals. Orthopaedics. 2017;40(3):e405–e12. 10.3928/01477447-20170223-04 [DOI] [PubMed] [Google Scholar]
- 13. Schmidtke KA, Evison F, Grove A, et al. : Surgical implementation gap: an interrupted time series analysis with interviews examining the impact of surgical trials on surgical practice in England. BMJ Qual Saf. 2023;32(6):341–56. 10.1136/bmjqs-2022-015077 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Shamseer L, Moher D, Clarke M, et al. : Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350: g7647. 10.1136/bmj.g7647 [DOI] [PubMed] [Google Scholar]
- 15. Moher D, Liberati A, Tetzlaff J, et al. : Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097. 10.1371/journal.pmed.1000097 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Wartolowska K, Judge A, Hopewell S, et al. : Use of placebo controls in the evaluation of surgery: systematic review. BMJ. 2014;348: g3253. 10.1136/bmj.g3253 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Costa ML, Achten J, Parsons NR, et al. : Percutaneous fixation with Kirschner wires versus volar locking plate fixation in adults with dorsally displaced fracture of distal radius: Randomised Controlled Trial. BMJ. 2014;349: g4807. 10.1136/bmj.g4807 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Moher D, Hopewell S, Schulz KF, et al. : CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340: c869. 10.1136/bmj.c869 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. NIHR: Improving inclusion of under-served groups in clinical research: guidance from INCLUDE project.2020; [Accessed date 18 January 2022]. Reference Source
- 20. Loudon K, Treweek S, Sullivan F, et al. : The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350: h2147. 10.1136/bmj.h2147 [DOI] [PubMed] [Google Scholar]
- 21. Hicks A, Fairhurst C, Torgerson DJ: A simple technique investigating baseline heterogeneity helped to eliminate potential bias in meta-analyses. J Clin Epidemiol. 2018;95:55–62. 10.1016/j.jclinepi.2017.10.001 [DOI] [PubMed] [Google Scholar]
- 22. Prestmo A, Hagen G, Sletvold O, et al. : Comprehensive geriatric care for patients with hip fractures: a prospective, randomised, controlled trial. Lancet. 2015;385(9978):1623–33. 10.1016/S0140-6736(14)62409-0 [DOI] [PubMed] [Google Scholar]
- 23. HIP ATTACK Investigators: Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial. Lancet. 2020;395(10225):698–708. 10.1016/S0140-6736(20)30058-1 [DOI] [PubMed] [Google Scholar]
- 24. Palmer AJR, Ayyar Gupta V, Fernquest S, et al. : Arthroscopic hip surgery compared with physiotherapy and activity modification for the treatment of symptomatic Femoroacetabular Impingement: multicentre Randomised Controlled Trial. BMJ. 2019;364:l185. 10.1136/bmj.l185 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Beard DJ, Rees JL, Cook JA, et al. : Arthroscopic Subacromial Decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial. Lancet. 2018;391(10118):329–38. 10.1016/S0140-6736(17)32457-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Beard DJ, Davies LJ, Cook JA, et al. : The clinical and cost-effectiveness of total versus Partial Knee Replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a Randomised Controlled Trial. Lancet. 2019;394(10200):746–56. 10.1016/S0140-6736(19)31281-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Willett K, Keene DJ, Mistry D, et al. : Close contact casting vs surgery for initial treatment of unstable ankle fractures in older adults: a Randomized Clinical Trial. JAMA. 2016;316(14):1455–63. 10.1001/jama.2016.14719 [DOI] [PubMed] [Google Scholar]
- 28. Reijman M, Eggerding V, Van Es E, et al. : Early surgical reconstruction versus rehabilitation with elective delayed reconstruction for patients with Anterior Cruciate Ligament rupture: COMPARE Randomised Controlled Trial. BMJ. 2021;372:n375. 10.1136/bmj.n375 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. van de Graaf VA, Noorduyn JCA, Willigenburg NW, et al. : Effect of early surgery vs Physical Therapy on knee function among patients with nonobstructive meniscal tears: the ESCAPE Randomized Clinical Trial. JAMA. 2018;320(13):1328–37. 10.1001/jama.2018.13308 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Costa ML, Achten J, Griffin J, et al. : Effect of locking plate fixation vs intramedullary nail fixation on 6-month disability among adults with displaced fracture of the distal tibia: the UK FixDT Randomized Clinical Trial. JAMA. 2017;318(18):1767–76. 10.1001/jama.2017.16429 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Rämö L, Sumrein BO, Lepola V, et al. : Effect of surgery vs functional bracing on functional outcome among patients with closed displaced humeral shaft fractures: the FISH Randomized Clinical Trial. JAMA. 2020;323(18):1792–801. 10.1001/jama.2020.3182 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Ghogawala Z, Terrin N, Dunbar MR, et al. : Effect of ventral vs dorsal spinal surgery on patient-reported physical functioning in patients with cervical spondylotic myelopathy: a Randomized Clinical Trial. JAMA. 2021;325(10):942–51. 10.1001/jama.2021.1233 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Kise NJ, Risberg MA, Stensrud S, et al. : Exercise therapy versus Arthroscopic Partial Meniscectomy for degenerative meniscal tear in middle aged patients: Randomised Controlled Trial with two year follow-up. Br J Sports Med. 2016;50(23):1473–80. 10.1136/bjsports-2016-i3740rep [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) Investigators: Fracture fixation in the operative management of hip fractures (FAITH): an international, multicentre, Randomised Controlled Trial. Lancet. 2017;389(10078):1519–27. 10.1016/S0140-6736(17)30066-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Griffin DR, Dickenson EJ, Wall PDH, et al. : Hip arthroscopy versus best conservative care for the treatment of Femoroacetabular Impingement syndrome (UK FASHIoN): a multicentre Randomised Controlled Trial. Lancet. 2018;391(10136):2225–35. 10.1016/S0140-6736(18)31202-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Ghogawala Z, Dziura J, Butler WE, et al. : Laminectomy plus fusion versus laminectomy alone for lumbar spondylolisthesis. N Engl J Med. 2016;374(15):1424–34. 10.1056/NEJMoa1508788 [DOI] [PubMed] [Google Scholar]
- 37. Rangan A, Brealey SD, Keding A, et al. : Management of adults with primary frozen shoulder in secondary care (UK FROST): a multicentre, pragmatic, three-arm, superiority randomised clinical trial. Lancet. 2020;396(10256):977–89. 10.1016/S0140-6736(20)31965-6 [DOI] [PubMed] [Google Scholar]
- 38. Griffin D, Parsons N, Shaw E, et al. : Operative versus non-operative treatment for closed, displaced, intra-articular fractures of the calcaneus: Randomised Controlled Trial. BMJ. 2014;349: g4483. 10.1136/bmj.g4483 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Försth P, Ólafsson G, Carlsson T, et al. : A randomized, controlled trial of fusion surgery for lumbar spinal stenosis. N Engl J Med. 2016;374(15):1413–23. 10.1056/NEJMoa1513721 [DOI] [PubMed] [Google Scholar]
- 40. Skou ST, Roos EM, Laursen MB, et al. : A randomized, controlled trial of total knee replacement. N Engl J Med. 2015;373(17):1597–606. 10.1056/NEJMoa1505467 [DOI] [PubMed] [Google Scholar]
- 41. Clark W, Bird P, Gonski P, et al. : Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;388(10052):1408–16. 10.1016/S0140-6736(16)31341-1 [DOI] [PubMed] [Google Scholar]
- 42. Paavola M, Malmivaara A, Taimela S, et al. : Subacromial decompression versus diagnostic arthroscopy for shoulder impingement: randomised, placebo surgery controlled clinical trial. BMJ. 2018;362: k2860. 10.1136/bmj.k2860 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Dias JJ, Brealey SD, Fairhurst C, et al. : Surgery versus cast immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label, randomised superiority trial. Lancet. 2020;396(10248):390–401. 10.1016/S0140-6736(20)30931-4 [DOI] [PubMed] [Google Scholar]
- 44. Bailey CS, Rasoulinejad P, Taylor D, et al. : Surgery versus conservative care for persistent sciatica lasting 4 to 12 months. N Engl J Med. 2020;382(12):1093–102. 10.1056/NEJMoa1912658 [DOI] [PubMed] [Google Scholar]
- 45. Costa ML, Achten J, Ooms A, et al. : Surgical fixation with K-wires versus casting in adults with fracture of distal radius: DRAFFT2 multicentre randomised clinical trial. BMJ. 2022;376: e068041. 10.1136/bmj-2021-068041 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Rangan A, Handoll H, Brealey S, et al. : Surgical vs nonsurgical treatment of adults with displaced fractures of the proximal humerus: the PROFHER randomized clinical trial. JAMA. 2015;313(10):1037–47. 10.1001/jama.2015.1629 [DOI] [PubMed] [Google Scholar]
- 47. Firanescu CE, De Vries J, Lodder P, et al. : Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial. BMJ. 2018;361(361): k1551. 10.1136/bmj.k1551 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Wallace N, O'Keeffe S, Gardner H, et al. : Underrecording and underreporting of participant ethnicity in clinical trials is persistent and is a threat to inclusivity and generalizability. J Clin Epidemiol. 2023;162:81–9. 10.1016/j.jclinepi.2023.08.008 [DOI] [PubMed] [Google Scholar]
- 49. Jeraj S, Butt J: Musculoskeletal conditions and Black, Asian and minority ethnic people: addressing health inequalities.Race Equality Foundation;2020. Reference Source
- 50. Health Research Authority: Public perceptions of research. 2023; [updated 21 Nov 2023]. Reference Source
- 51. Wilson C, Rooshenas L, Paramasivan S, et al. : Development of a framework to improve the process of recruitment to Randomised Controlled Trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework. Trials. 2018;19(1): 50. 10.1186/s13063-017-2413-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Davies L, Beard D, Cook JA, et al. : The challenge of equipoise in trials with a surgical and non-surgical comparison: a qualitative synthesis using meta-ethnography. Trials. 2021;22(1): 678. 10.1186/s13063-021-05403-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Scantlebury A, McDaid C, Brealey S, et al. : Embedding qualitative research in Randomised Controlled Trials to improve recruitment: findings from two recruitment optimisation studies of orthopaedic surgical trials. Trials. 2021;22(1): 461. 10.1186/s13063-021-05420-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Crocker JC, Ricci-Cabello I, Parker A, et al. : Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. BMJ. 2018;363: k4738. 10.1136/bmj.k4738 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Health Research Authority: Types of health and care information and the legal frameworks protecting them. 2022; [updated 5 Dec 2022]. Reference Source
- 56. Shepherd V, Joyce K, Flynn S, et al. : INCLUDE impaired capacity to consent framework.2022; [Accessed date 12 July 2023]. Reference Source
- 57. Hopewell S, Clarke M, Lefebvre C, et al. : Handsearching versus electronic searching to identify reports of randomized trials. Cochrane Database Syst Rev. 2007;2007(2): MR000001. 10.1002/14651858.MR000001.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. NIHR: Best research for best health: the next chapter. National Institute of Health Research,2021. Reference Source
- 59. Shiely F, Rychlíčková J, Kubiak C, et al. : Training and education on inclusivity in clinical trials—the SENSITISE project. Trials. 2024;25(1): 318. 10.1186/s13063-024-08150-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Biggs K, Hullock K, Dix C, et al. : Time to STEP UP: methods and findings from the development of guidance to help researchers design inclusive clinical trials. BMC Med Res Methodol. 2024;24(1): 227. 10.1186/s12874-024-02342-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. NIHR: Inclusive research design to become an NIHR condition of funding. [Accessed date 16 October 2024]. Reference Source
- 62. Health Research Authority: HRA and MHRA draft inclusion and diversity guidance. [Accessed date 16 October 2024]. Reference Source
- 63. Vayena E, Blasimme A, Sugarman J: Decentralised clinical trials: ethical opportunities and challenges. Lancet Digit Health. 2023;5(6):e390–e4. 10.1016/S2589-7500(23)00052-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Dawson S, Banister K, Biggs K, et al. : Trial forge guidance 3: randomised trials and how to recruit and retain individuals from ethnic minority groups—practical guidance to support better practice. Trials. 2022;23(1): 672. 10.1186/s13063-022-06553-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Averbuch T, Mohamed MO, Islam S, et al. : The association between Socioeconomic Status, sex, race / ethnicity and in-hospital mortality among patients hospitalized for heart failure. J Card Fail. 2022;28(5):697–709. 10.1016/j.cardfail.2021.09.012 [DOI] [PubMed] [Google Scholar]
- 66. Cheng AL, Bradley EC, Brady BK, et al. : The influence of race, sex, and social disadvantage on self-reported health in patients presenting with chronic musculoskeletal pain. Am J Phy Med Rehabil. 2022;101(3):211–6. 10.1097/PHM.0000000000001774 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Brealey S: Supporting materials for review of high impact journals about inclusivity in orthopaedic surgical randomised trials. figshare. 2024; [cited 2025 Jan 6]. https://figshare.com/articles/journal_contribution/Detailed_description_of_the_eligibility_criteria_and_patient_population/27074599/3 [Google Scholar]

